TY - JOUR
T1 - CDKN2B-AS1 as a novel therapeutic target in cancer
T2 - Mechanism and clinical perspective
AU - Hjazi, Ahmed
AU - Ghaffar, Eishah
AU - Asghar, Waqas
AU - Alauldeen Khalaf, Hasan
AU - Ikram Ullah, Muhammad
AU - Mireya Romero-Parra, Rosario
AU - Hussien, Beneen M.
AU - Abdulally Abdulhussien alazbjee, Adeeb
AU - Singh Bisht, Yashwant
AU - Fakri Mustafa, Yasser
AU - Reza Hosseini-Fard, Seyed
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/7
Y1 - 2023/7
N2 - Long non-coding RNAs (lncRNA) have been identified as essential components having considerable modulatory impacts on biological activities through altering gene transcription, epigenetic changes, and protein translation. Cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), a recently discovered lncRNA, was shown to be substantially elevated in various cancers. Furthermore, via modulation of various signaling axes, it is effectively connected to the control of critical cancer-associated biological pathways like cell proliferation, apoptosis, cell cycle, epithelial–mesenchymal transition (EMT), invasion, and migration. Considering the crucial functions of CDKN2B-AS1 in cancer onset and development, this lncRNA offers immense therapeutic implications for usage as a new diagnostic or treatment approach. In this article, we evaluate the most recent discoveries made into the functions of the lncRNA CDKN2B-AS1 in cancer, in addition to its prospect as beneficial properties, prognostic and diagnostic biomarkers in the cancer-related treatment, emphasizing its participation in a broad network of signaling axes which could affect various cancers and investigating its promising therapeutic possibility.
AB - Long non-coding RNAs (lncRNA) have been identified as essential components having considerable modulatory impacts on biological activities through altering gene transcription, epigenetic changes, and protein translation. Cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), a recently discovered lncRNA, was shown to be substantially elevated in various cancers. Furthermore, via modulation of various signaling axes, it is effectively connected to the control of critical cancer-associated biological pathways like cell proliferation, apoptosis, cell cycle, epithelial–mesenchymal transition (EMT), invasion, and migration. Considering the crucial functions of CDKN2B-AS1 in cancer onset and development, this lncRNA offers immense therapeutic implications for usage as a new diagnostic or treatment approach. In this article, we evaluate the most recent discoveries made into the functions of the lncRNA CDKN2B-AS1 in cancer, in addition to its prospect as beneficial properties, prognostic and diagnostic biomarkers in the cancer-related treatment, emphasizing its participation in a broad network of signaling axes which could affect various cancers and investigating its promising therapeutic possibility.
KW - Cancer
KW - CDKN2B-AS1
KW - LncRNA
KW - NcRNA
UR - https://www.scopus.com/pages/publications/85163383302
U2 - 10.1016/j.bcp.2023.115627
DO - 10.1016/j.bcp.2023.115627
M3 - Review article
C2 - 37257723
AN - SCOPUS:85163383302
SN - 0006-2952
VL - 213
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
M1 - 115627
ER -
